7-amino-1-(4-(trifluoromethyl)phenyl)heptan-1-one | 1039037-68-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 7-amino-1-(4-(trifluoromethyl)phenyl)heptan-1-one
• 英文别名: 7-Amino-1-[4-(trifluoromethyl)phenyl]heptan-1-one
• CAS: 1039037-68-7
• 化学式: C₁₄H₁₈F₃NO
• 分子量: 273.298
• InChiKey: QKKDVKUPBMXALS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazole-4-carboxylic acid 、 7-amino-1-(4-(trifluoromethyl)phenyl)heptan-1-one 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 70.0h， 以50%的产率得到2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazole-4-carboxylic acid {7-[4-(trifluoromethyl)-phenyl]-7-oxo-heptyl}amide
  参考文献：
  名称：

  WO2008/84057

  摘要：

  公开号：

文献信息

• Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient
  申请人：Hatayama Akira

  公开号：US20060111303A1

  公开（公告）日：2006-05-25

  The present invention relates to a diketohydrazine derivative of formula (I) and a pharmaceutically acceptable salt thereof (the symbols in the formula have the same meaning as described in the specification). The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory activity against elastase and it is also useful for the treatment of COPD (chronic obstacle pulmonary diseases).

  本发明涉及一种公式（I）的二酮肼衍生物及其药学上可接受的盐（公式中的符号与说明书中描述的含义相同）。公式（I）的化合物具有对半胱氨酸蛋白酶的抑制活性，可用于治疗炎症性疾病、免疫性疾病、缺血性疾病、呼吸系统疾病、循环系统疾病、血液疾病、神经系统疾病、肝胆系统疾病、骨骼或关节疾病、代谢性疾病等。该化合物具有对弹性蛋白酶的抑制活性，也可用于慢性阻塞性肺疾病（COPD）的治疗。
• COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION
  申请人：Lange Josephus H.M.

  公开号：US20080214559A1

  公开（公告）日：2008-09-04

  Compounds with a combination of cannabinoid CB 1 antagonism and serotonin re-uptake inhibition, pharmaceutical compositions containing these compounds, methods for preparing these compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing these compositions are disclosed. Uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity, drug dependence, Parkinson's disease, Alzheimer's disease, pain disorders, neuropathic pain disorders and sexual disorders are disclosed. In at least one embodiment, the invention relates to compounds of the general formula (1); wherein the substitutents have the definitions given in the specification.

  本发明涉及一种具有大麻素CB1拮抗和血清素再摄取抑制的化合物组合，含有这些化合物的制药组合物，制备这些化合物的方法，制备用于其合成的新型中间体的方法，以及制备这些组合物的方法。本发明还涉及这些化合物和组合物的用途，特别是将它们用于给患者施用，以在精神病、焦虑、抑郁、注意力缺陷、认知障碍、肥胖症、药物依赖、帕金森病、阿尔茨海默病、疼痛障碍、神经痛障碍和性障碍中实现治疗效果。在至少一个实施例中，本发明涉及一般式（1）的化合物；其中取代基具有规范中给出的定义。
• DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：Hatayama Akira

  公开号：US20100087442A1

  公开（公告）日：2010-04-08

  The present invention relates to a diketohydrazine derivative of formula (I) and a pharmaceutically acceptable salt thereof (the symbols in the formula have the same meaning as described in the specification). The compound of formula (I) has an inhibitory activity against cysteine protease, and it is useful for the treatment of inflammatory diseases, immune diseases, ischemic diseases, respiratory diseases, circulatory diseases, blood diseases, neuronal diseases, hepatic or biliary diseases, osseous or articular diseases, metabolic diseases, etc. And the compound has inhibitory activity against elastase and it is also useful for the treatment of COPD (chronic obstacle pulmonary diseases).

  本发明涉及式(I)的二酮肼衍生物及其药学上可接受的盐（式中符号与说明书中描述的含义相同）。式(I)化合物具有对半胱氨酸蛋白酶的抑制活性，可用于治疗炎症性疾病、免疫性疾病、缺血性疾病、呼吸系统疾病、循环系统疾病、血液疾病、神经系统疾病、肝胆系统疾病、骨骼或关节疾病、代谢性疾病等。该化合物具有对弹性蛋白酶的抑制活性，也可用于治疗慢性阻塞性肺部疾病（COPD）。
• COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION
  申请人：Solvay Pharmaceuticals B.V.

  公开号：EP2111394A1

  公开（公告）日：2009-10-28
• US8138174B2
  申请人：——

  公开号：US8138174B2

  公开（公告）日：2012-03-20